Posttest - Tumor Board Tuesday - September 28, 2021 (ID: i788-18)

Question Title

* 1. Please list your first name, last name, and email:

First name:

Last name:

Email:

Question Title

* 2. What is your specialty?

Question Title

* 3. How many patients with thyroid cancer do you treat each week?

1 to 10

11 to 25

26 to 50

I am not directly involved in patient care

Question Title

* 4. What is the most common actionable alteration in sporadic medullary thyroid cancer?

RET mutation

BRAF mutation

RET fusion

NTRK fusion

Question Title

* 5. What would be the most appropriate treatment option for RET V804 M gatekeeper mutant thyroid cancer?

Selpercatinib or pralsetinib

Vandetanib or pazopanib

Cabozantinib or sorafenib

Sunitinib or lenvatinib